• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Academic radiology >Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. Adapted Choi Criteria Can Reflect Early Therapy Response Better than Does RECIST.
【24h】

Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. Adapted Choi Criteria Can Reflect Early Therapy Response Better than Does RECIST.

机译：BRAF抑制剂治疗转移性黑素瘤患者的治疗反应评估。 适应的Choi标准可以比再次恢复更好地反映早期治疗反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Targeted therapy can lead to considerable tumor reduction and may result initially in altered tissue at constant tumor size. In this setting, Response Evaluation Criteria in Solid Tumors (RECIST) can be inadequate for assessing early treatment response. Choi-criteria combine both size and density measurements. Our purpose was to evaluate computed tomography (CT) images of melanoma patients under BRAF-inhibitor therapy according to Choi-criteria which were adapted to our study (aChoi). Material and Methods: Twelve patients (four male, eight female, mean age 49) with stage IV melanoma treated with a BRAF inhibitor were included. Response was assessed according to RECIST for 39 lesions in contrast-enhanced CT. Target volumes are semiautomatically segmented to calculate mean density for aChoi-criteria, thus using a two-dimensional nonstandardized region of interest could be prevented. Results: Eight patients are RECIST responders. aChoi-criteria indicate therapy response earlier compared to RECIST in five of eight patients. In seven cases, tumor density in CT had decreased 8 weeks after therapy start, whereas in some cases tumor size diminished less or even increased. Response according to aChoi was diagnosed in seven patients who showed in RECIST-evaluation stable disease in five and partial response in two cases. Fifteen weeks after therapy start almost all patients within the aChoi responders were RECIST responders, too. Only one aChoi responder showed still stable disease in RECIST. Conclusion: Our initial data indicate that aChoi-criteria can reflect response to vemurafenib earlier compared to RECIST. This is of clinical significance as BRAF-inhibitors are cost-intensive targeted therapies and can cause severe side effects, so criteria for early therapy response have to be evaluated.
机译：用途：靶向治疗可能会导致相当大的肿瘤减小并且可能导致最初在恒定的肿瘤大小改变的组织。在该设置中，在实体瘤（RECIST）反应评价标准可以是不充分的用于评估早期治疗反应。财标准则结合了两者的大小和密度测量。我们的目的是，根据该被适配成我们的研究（aChoi）财标准来评估BRAF抑制剂治疗下黑素瘤患者的计算机断层扫描（CT）图像。材料和方法：12例（四只雄性，8女性，平均年龄49）与具有BRAF抑制剂处理的阶段IV期黑素瘤患者。响应根据RECIST 39个病变增强CT评估。目标卷半自动分段以计算平均密度为aChoi准则，从而使用可以防止感兴趣的二维非标准化区域。结果：8例患者是RECIST反应。 aChoi准则表明治疗的反应更早相比，RECIST八5例。 7例，在CT肿瘤密度开始治疗8周后已经减少，而在某些情况下，肿瘤大小减小较少或者甚至增加。根据aChoi响应被确诊7例谁在两种情况五个部分反应表明在RECIST评价病情稳定。在aChoi反应内几乎所有十五个星期治疗后开始患者RECIST反应了。只有一个aChoi响应者仍表现出疾病稳定RECIST。结论：我们的初步数据表明，aChoi准则可以反映较早响应于威罗菲尼相比RECIST。这是临床意义如BRAF抑制剂是成本密集型的​​靶向疗法，并可能导致严重的副作用，因此对于早期治疗反应标准必须被评估。

著录项

  • 来源
    《Academic radiology》 |2013年第4期|共7页
  • 作者

    UhrigM.; HasselJ.C.; SchlemmerH.-P.; GantenM.-K.;

  • 作者单位

    German Cancer Research Center (DKFZ) Heidelberg Department of Radiology Im Neuenheimer Feld 280;

    National Center for Tumor Diseases (NCT) Heidelberg Im Neuenheimer Feld 460 D-69120 Heidelberg;

    German Cancer Research Center (DKFZ) Heidelberg Department of Radiology Im Neuenheimer Feld 280;

    German Cancer Research Center (DKFZ) Heidelberg Department of Radiology Im Neuenheimer Feld 280;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 放射医学;
  • 关键词

    Choi; Melanoma; RECIST; Response criteria; Targeted therapy;

    机译：choi;黑色素瘤;重新入住;响应标准;有针对性的治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号